1A study on the evaluation criteria of medical insurance negotiation admittance for innovative drugs in typical countries and its enlightenment to ChinaYAO Wen, YAN Jian-zhou, SHAO Rong1057-10622Interpretation of the antimicrobial effectiveness test of Chinese Pharmacopoeia 2020 editionLI Hui, ZHOU Fa-you, YANG Xiao-li, MA Shi-hong, SHENG Jin-fang1063-10673Patent application analysis of histone deacetylase inhibitorsWANG Wei, XUE Jian-qiang1068-10724The experience of managed entry scheme for high-value drugs of Australia and its implication to ChinaTANG Jing-qi, ZHANG Xiao1073-10785Immunomodulatory effect of lycium barbarum polysaccharide of different molecular weights on macrophage RAW264.7WANG Ying, JIN Hong-yu, LI Yao-lei, DONG Xiao-xu, ZAN Ke, MA Shuang-cheng1079-10866Determination of MBS77E,a monoclonal antibody against Ebola virus,in monkey serum by indirect enzyme-linked immunosorbent assay (ELISA) and the pharmacokinetic studyXIANG Ya-nan, GAO You, LUO Long-long, ZHANG Wen-peng, ZHUANG Xiao-mei1087-10927Comparative study on chemical composition and pharmacological action of Radix paeoniae alba and Radix paeoniae rubra and predictive analysis of quality markersWANG Qian, LI Liu-tong, MA Yong-ben, WU Ling-fang, NIU Li-ying1093-10988Analysis of follow-up for subjects of anti-cancer clinical trials under COVID-19LI Dan, LIU Xiao-hong, LU Dong-qing, JIAN Kang1099-11029Protective effect of gardenoside on dementia-like mice induced by tail intravenous injection of streptozotocinHUANG Jia-qing, WEN Wu, L(U) Xin, JIANG Meng-meng, DING Wang-li, ZHAO Jia-hui, GONG Yue-song1103-110910Identification of related substances in mesaconine by ultra-high performance liquid chromatography tandem mass spectrometryWU Xue-ting, LIU Xiu-xiu, QIAN Guang-sheng, CHAO Ruo-bing1110-111611Analysis of polymer impurities in ceftazidime averbatan sodium for injectionLI Jin, YAO Shang-chen, YIN Li-hui, XU Ming-zhe, HU Chang-qin1117-112512Determination of mannitol in somatostatin for injection by HPLC-CADZHANG Wei, ZHANG Hui, LI Jing, SUN Yue, LI Yi, LIANG Cheng-gang1126-113113An initiative to establish coordinated and consistent causality assessment criteria for adverse drug reaction in clinical trialsHUANG Qian, WEN Ze-huai1132-113614A rapid health technology assessment of pembrolizumab in first-line therapy for locally advanced/metastatic non-small cell lung cancerLIU Yi, HUANG Lin, MEN Peng, YANG Yi-heng, FENG Yu-fei, FAN Rong-rong, LIU Yan-guo1137-114615An analysis of medical resource utilization in intra-abdominal infectious patients treated with latamoxefTONG Xun-liang, XIAO Ruo-wei, LI Wei, ZENG Chun-ying, WU Jian-mei, HAN Sheng1147-1152 